TrialAnnals of the rheumatic diseases2006

Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.

M Vis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.